<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; regulator</title>
	<atom:link href="http://www.tapanray.in/tag/regulator/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Even Smaller Countries Now Question Indian Drug Quality Standard</title>
		<link>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=even-smaller-countries-now-question-indian-drug-quality-standard</link>
		<comments>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/#comments</comments>
		<pubDate>Sun, 04 Dec 2016 23:42:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vietnam]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8001</guid>
		<description><![CDATA[India has over 135 US-FDA approved pharmaceutical manufacturing units, at present. This number is very significant ranking second behind the United States, and was driving the growth of generic drug exports in the top pharma market of the world. Riding &#8230; <a href="http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDC Saga: Defiant Manufacturers, Sloppy Regulators and Humongous Inaction</title>
		<link>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction</link>
		<comments>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/#comments</comments>
		<pubDate>Mon, 15 Jul 2013 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[handsome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[inaction]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[retraction]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[scenario]]></category>
		<category><![CDATA[slack]]></category>
		<category><![CDATA[sloppy]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2921</guid>
		<description><![CDATA[&#8220;TO SIN BY SILENCE WHEN THEY SHOULD PROTEST MAKES COWARDS OF MEN&#8221;       &#8211; Abraham Lincoln The ghost of untested, irrational and even of bizarre kind of Fixed Dose Combination (FDC) drugs, which continue to be launched, promoted, prescribed &#8230; <a href="http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond &#8216;The Magic Moment&#8217; of New Drug Marketing Approval</title>
		<link>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-magic-moment-of-new-drug-marketing-approval</link>
		<comments>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/#comments</comments>
		<pubDate>Mon, 24 Jun 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adaptive]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[AL]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredient]]></category>
		<category><![CDATA[Jangle]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhaseIV]]></category>
		<category><![CDATA[pst]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[surveillance]]></category>
		<category><![CDATA[Tacfidera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncontrolled]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2394</guid>
		<description><![CDATA[“Uncontrolled clinical trials are causing havoc to human life. There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far.” This is exactly what the Supreme Court of India observed &#8230; <a href="http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Havoc’ and its ‘Aftermath’: Clinical Trials in India</title>
		<link>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=havoc-and-its-aftermath-clinical-trials-in-india</link>
		<comments>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/#comments</comments>
		<pubDate>Mon, 14 Jan 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[aftermath]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[havoc]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[Parialmentary]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[volunteer]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1427</guid>
		<description><![CDATA[Just as the New Year dawned, on January 3, 2013, in an embarrassing indictment to the Government, the bench of honorable justices R.M Lodha and A.R Dave of the Supreme Court reportedly observed that uncontrolled Clinical Trials (CT) are creating &#8230; <a href="http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Indian Drug Regulator Accords Primacy to Pharma Industry Instead of Safegurding Public Health and Safety” – Parliamentary Committee</title>
		<link>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee</link>
		<comments>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/#comments</comments>
		<pubDate>Mon, 28 May 2012 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Accords]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Instead]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Primacy]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safegurding]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=88</guid>
		<description><![CDATA[The Department Related Parliamentary Committee on Health and Family Welfare presented its 59th Report of 118 pages in total on the functioning of the Indian Drug Regulator &#8211; the Central Drug Standards Control Organization (CDSCO) in both the houses of &#8230; <a href="http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-regulator-accords-primacy-to-pharma-industry-instead-of-safegurding-public-health-and-safety-parliamentary-committee/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the UNDILUTED ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/#comments</comments>
		<pubDate>Sun, 31 Jan 2010 01:30:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=476</guid>
		<description><![CDATA[Many industry experts after having carefully evaluated the provisions of the original draft of the proposal of forming a CDA in the country commended and supported this praiseworthy initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
